Proprietary Product Portfolio

Hovione’s product portfolio consists of innovative, proprietary drug products in the areas of Dermatology, Ophthalmology, and Respiratory.

Hovione’s product portfolio is comprised of known Active Pharmaceutical Ingredients (APIs) which have been formulated to meet patient needs by increasing safety, improving compliance or expanding access by following the FDA 505(b)2 regulatory pathway. We focus on the fields of dermatologyophthalmology and respiratory and target new routes of administration, expansion of indications and improved delivery. Hovione develops its products through Phase 1/2 and seeks partners for completion of the clinical development, regulatory approval, and commercialization.

Product List
 

DERMATOLOGY
Product Condition Dosage Form Formulation
Development
Non-Clinical Clinical Phase 1/2 Partnering
HY01 Inflammatory
skin conditions
Topical Gel Completed Completed Phase 1 Completed Available
 
OPHTHALMOLOGY
Product Condition Dosage Form Formulation
Development
Non-Clinical Clinical Phase 1/2 Partnering
HY02 Front of eye
inflamation
Sterile ointment Completed On-going 2017 Available
HO10 Retinal Disease Injection UNAVAILABLE Co-development

 

RESPIRATORY
Product Condition Dosage Form Formulation
Development
Non-Clinical Clinical Phase 1/2 Partnering
IH11 Asthma TwinCaps® DPI On-going     Available

 

To learn more about our projects please contact our team.

 

Related Files

Also in Proprietary Product Licensing